Glycogen Storage Diseases

• Accumulation of structurally abnormal or excessive glycogen in hepatocytes, myocytes, and other tissues: When degradative enzymes are deficient (GSD Types III, IV, V, VI, VII, IX), glycogen cannot be completely mobilized, leading to progressive accumulation of structurally abnormal glycogen molecules. In GSDs with branching enzyme deficiency (GSD IV), the resulting glycogen lacks normal branching architecture, forming polyglucosan bodies that trigger chronic inflammation, hepatocyte necrosis, and eventual cirrhosis. In debranching enzyme deficiency (GSD III), the outer tiers of glycogen are accessible to phosphorylase, but the inner α-1,6-linked branches cannot be cleaved, leaving dead-end glycogen that accumulates and causes massive hepatomegaly and myopathy. The physical presence of this abnormal glycogen disrupts normal cellular architecture and function.

• Severe hypoglycemia from inability to maintain hepatic glucose output during fasting: In glucose-6-phosphatase deficiency (GSD I, Von Gierke disease) and glycogen phosphorylase deficiency affecting liver (GSD VI, IX), the fundamental problem is failure to convert glucose-6-phosphate to free glucose, preventing hepatic glucose production during fasting periods. After just 3-4 hours without food intake, hepatic glycogen reserves become depleted, blood glucose drops precipitously to levels of 20-40 mg/dL, triggering severe hypoglycemic symptoms including seizures and loss of consciousness. This occurs because gluconeogenesis is blocked at the same point (glucose-6-phosphatase) in both glycogenolysis and gluconeogenesis pathways, making the liver unable to produce glucose through either mechanism. The severity is proportional to the duration of fasting, with nocturnal hypoglycemia being particularly problematic in infants and young children who cannot maintain oral intake during sleep.

• Hepatomegaly from massive glycogen accumulation and impaired hepatic function: Liver accounts for approximately 10% of body weight but stores 70-100 grams of glycogen in the fed state; in severe GSDs like Type I, hepatic glycogen content may exceed 300-400 grams, causing livers to weigh 2-3 times normal. The accumulated glycogen physically enlarges hepatocytes, compressing sinusoids and impairing blood flow, which contributes to secondary complications including hepatic steatosis from excessive lipogenesis (livers become bright yellow from lipid content), hepatic fibrosis, and eventual cirrhosis. The impaired hepatic synthetic function leads to reduced albumin production and coagulation factor synthesis, increasing risk of bleeding complications. In some GSDs, the glycogen accumulation triggers inflammatory pathways and hepatocyte apoptosis, accelerating progression to end-stage liver disease.

• Impaired muscle energy metabolism and exercise intolerance in muscle-type GSDs: Muscle phosphorylase deficiency (GSD V, McArdle disease) and other myopathic GSDs prevent glycogen mobilization within muscle cells, depriving myocytes of their primary fuel source during exercise. During aerobic exercise, muscles normally shift from relying on blood glucose to mobilizing intramuscular glycogen, but without functional phosphorylase, this pathway is blocked. Myocytes attempt to generate ATP through oxidative phosphorylation of circulating glucose and fatty acids, but this is insufficient for the ATP demands of sustained exercise, leading to rapid energy depletion, muscle cramps, myoglobinuria, and potential rhabdomyolysis with acute renal failure. The second-wind phenomenon observed in McArdle patients (exercise becomes tolerable after 8-10 minutes) occurs because increased cardiac output delivers sufficient blood glucose and fatty acids to meet myocyte ATP demands once they adapt to non-glycogenic fuel sources.

• Chronic metabolic acidosis and hyperuricemia from shunting of glucose-6-phosphate into alternative pathways: When glycogenolysis cannot proceed normally, glucose-6-phosphate accumulates and is shunted into alternative metabolic pathways, particularly gluconeogenesis and the pentose phosphate pathway. Excessive flux through gluconeogenesis increases production of acetyl-CoA and NADH, which drives hepatic lipogenesis producing massive quantities of triglycerides and free fatty acids; these fatty acids undergo β-oxidation producing ketone bodies and contributing to lactic acidosis. The accumulation of lactate (blood levels 2-5 mmol/L compared to normal <2 mmol/L) represents the metabolic signature of severe hepatic GSDs. Additionally, increased purine degradation from excessive AMP deamination secondary to impaired ATP regeneration increases uric acid production, with serum uric acid levels often reaching 8-12 mg/dL (normal <7 mg/dL), predisposing to early-onset gout, urate nephropathy, and progressive renal disease.

• Cardiomyopathy and cardiac dysfunction in glycogen-accumulating cardiac muscle: In glycogen storage disease of cardiac type (GSD II, Pompe disease) caused by acid alpha-glucosidase (GAA) deficiency, the enzyme normally degrades glycogen within lysosomes; without it, glycogen accumulates in cardiac myocytes within lysosomal structures, distorting the normal contractile architecture. Lysosomal rupture from glycogen accumulation triggers autophagy and apoptotic pathways, leading to myocyte loss and replacement fibrosis. The massive glycogen accumulation increases cardiac wall thickness creating restrictive or hypertrophic cardiomyopathy, increasing left ventricular mass index 2-3 fold above normal. This leads to diastolic dysfunction (elevated filling pressures and reduced ventricular compliance) progressing to systolic dysfunction and heart failure, with infantile Pompe disease presenting with sudden cardiac death if untreated.

• GSD Type I (Von Gierke disease): Glucose-6-phosphatase deficiency: Mutations in the G6PC gene (chromosome 17q21) encoding glucose-6-phosphatase catalytic subunit, the enzyme responsible for the final step in both glycogenolysis and gluconeogenesis pathways. This is the most severe hepatic GSD, accounting for approximately 25% of all GSDs with incidence of 1 in 100,000. Represents the rate-limiting step for hepatic glucose production, making it the most hypoglycemia-prone GSD. Three subtypes exist based on transport protein defects (GSD Ib with neutropenia, GSD Ic with mild phenotype).

• GSD Type II (Pompe disease): Acid alpha-glucosidase deficiency: Mutations in the GAA gene encoding the lysosomal enzyme acid alpha-glucosidase; this is the only glycogen storage disease with primary lysosomal pathology rather than cytoplasmic accumulation. Most enzyme-deficiency disorders; occurs in both infantile form (onset before age 2 with rapid progression to death by age 2-3 without treatment) and late-onset form (slower progression with adult onset ranging from childhood to adulthood). Variable clinical severity correlates with residual enzyme activity; infantile form typically has <3% residual activity while late-onset may have 20-40% residual activity.

• GSD Type III (Cori disease): Glycogen debranching enzyme deficiency: Mutations in the AGL gene encoding the glycogen debranching enzyme complex (isoamylase and pullulanase activities). Relatively common, representing approximately 30% of GSDs with incidence around 1 in 100,000. Clinical severity varies based on which isoform is affected and tissue distribution, with GSD IIIa involving both liver and muscle being most common.

• GSD Type IV (Branching enzyme deficiency/Andersen disease): Glycogen branching enzyme deficiency: Mutations in the GBE1 gene (chromosome 3p12) encoding the glycogen branching enzyme (amylo-1,6-transglucosidase). Rarest hepatic GSD representing <5% of cases; produces the most severe hepatic pathology due to accumulation of structurally abnormal polyglucosan with reduced branching. Progressive cirrhosis almost invariable by age 5 without treatment.

• GSD Type V (McArdle disease): Muscle phosphorylase deficiency: Mutations in the PYGL gene encoding muscle glycogen phosphorylase, the rate-limiting enzyme for glycogen breakdown in skeletal muscle. Most common myopathic GSD with estimated prevalence of 1 in 100,000 to 1 in 200,000, though likely underdiagnosed. Skeletal muscle is the primary affected tissue; hepatic phosphorylase is encoded by a different gene (PYGB) and is typically normal, so hepatomegaly and hypoglycemia do not occur.

• GSD Type VI: Hepatic phosphorylase deficiency: Mutations in the PYGL or PHKG2 genes encoding hepatic/muscle phosphorylase or its kinase; similar clinical picture to GSD IX but generally milder. Phosphorylase kinase exists as a complex of multiple subunits, so defects in different kinase subunits produce variable severity. Accounts for approximately 10-15% of GSDs.

• GSD Type VII: Phosphofructokinase-1 deficiency: Rare myopathic GSD affecting glycolysis (not glycogenolysis) with muscle pain and myoglobinuria similar to GSD V, though glycogen accumulation is less prominent. Less common than GSD V with milder clinical phenotype in most cases.

• GSD Type IX: Phosphorylase kinase deficiency: Mutations in genes encoding the various subunits of the phosphorylase kinase complex (PHKA2, PHKB, PHKG2, PHKG1), with X-linked form being most common, particularly PHKA2 mutations accounting for ~50% of cases. Clinical phenotype varies from asymptomatic hepatomegaly discovered incidentally to moderate hepatomegaly with mild growth retardation and exercise intolerance. Generally prognosis is excellent with spontaneous improvement in many patients during adolescence and adulthood.

Hepatic Glycogen Storage Diseases (Types I, III, IV, VI, IX)

• Severe hypoglycemia and seizures: In infants with Type I GSD, hypoglycemia typically develops 3-4 hours after feeding and can be profound (20-40 mg/dL), presenting with irritability, poor feeding, tremor, seizures, and loss of consciousness. Parents often report seizures occurring in the early morning before breakfast or after missing meals. The lack of hepatic glucose output (in Type I) makes these patients extraordinarily sensitive to fasting, unable to tolerate overnight sleep without feeding and requiring meal frequencies of every 2-3 hours. Recurrent hypoglycemic seizures can cause cognitive impairment and permanent neurological damage if not aggressively managed.

• Massive hepatomegaly: Hepatomegaly is the hallmark physical finding in hepatic GSDs, with livers extending 3-5 cm below the costal margin even in young children; in severe cases (Type I), livers may extend to the pelvis in infants. The hepatomegaly is generally painless and non-tender but the distended abdomen with hepatomegaly creates a striking appearance with protuberant abdomen and relatively thin extremities. The massive hepatomegaly is often the presenting sign that brings patients to medical attention, sometimes noted on routine prenatal ultrasound or newborn physical examination.

• Growth retardation and "doll-like" facial appearance: Chronic metabolic derangements in hepatic GSDs cause growth hormone resistance, chronic hypoglycemia, and metabolic acidosis, all contributing to severe growth retardation with height typically at or below the 5th percentile. In Type I GSD, the characteristic "doll-like" facies includes full cheeks, short stature, and prominent lips from chronic lactic acidosis and delayed skeletal maturation. Puberty is typically delayed, with bone age significantly lagging behind chronological age.

• Lactic acidosis and chronic metabolic acidosis: The chronic metabolic acidosis presents as tachypnea, fatigue, and poor exercise tolerance. Serum lactate is markedly elevated (typically 2-5 mmol/L, compared to normal <2 mmol/L) even at rest, and increases further with fasting or exercise. Blood pH typically ranges from 7.25-7.35 (mildly acidemic) at baseline with acute decompensation causing more severe acidosis during illness or prolonged fasting.

• Gout and xanthomas: Hyperuricemia in Type I GSD (uric acid 8-12 mg/dL) leads to early-onset gout, sometimes manifesting in childhood with acute arthritis of the foot or hand; recurrent gout attacks can cause tophi and joint damage. The hyperlipidemia (triglycerides often 500-3000 mg/dL and cholesterol 300-600 mg/dL) causes eruptive xanthomas on the extensor surfaces and palms, as well as lipemia retinalis on fundoscopic examination.

• Bleeding tendency and hepatic dysfunction: Impaired hepatic synthetic function leads to coagulopathy with elevated prothrombin time and reduced platelet counts, manifesting as spontaneous bruising, epistaxis, or hemorrhage after minor trauma. Advanced cirrhosis develops in Types I and IV, with manifestations of portal hypertension including splenomegaly, ascites, varices, and eventual hepatic encephalopathy.

• Renal disease: Chronic hyperuricemia causes urate nephropathy with progressive chronic kidney disease; many Type I GSD patients develop proteinuria and declining glomerular filtration rate by young adulthood, with some progressing to end-stage renal disease requiring dialysis.

• Hepatic adenomas: Patients with Type I GSD who survive into late childhood and adulthood develop multiple hepatic adenomas (benign but large), visible on abdominal ultrasound or CT scan, which rarely undergo malignant transformation to hepatocellular carcinoma.

Myopathic Glycogen Storage Diseases (Types V, VII)

• Exercise intolerance and muscle cramps: In GSD V (McArdle disease), patients experience severe muscle cramping, weakness, and myalgia within minutes of starting exercise, often described as "dead leg" sensation. The cramping is typically exercise-limiting, with patients unable to continue activity, and is accompanied by a sensation of muscle tightness and heaviness. The "second wind" phenomenon is pathognomonic: after 8-10 minutes of rest, if the patient attempts to resume the same exercise, it becomes tolerable as alternative fuel sources (blood glucose and fatty acids delivered by increased

The three-second recognition patterns

• Von Gierke (I): hypoglycemia plus lactic acidosis, hyperuricemia, and hypertriglyceridemia in a doll-faced infant with a huge liver. The block sits at the shared exit point of glycogenolysis and gluconeogenesis, so lactate cannot be salvaged into glucose and rises instead — this is the single association examiners test.
• Pompe (II): floppy baby with macroglossia, feeding difficulty, and massive cardiomegaly on chest film, with normal blood glucose. Lysosomal acid α-glucosidase sits outside the cytosolic glycogenolytic pathway, so fasting glucose is preserved — "Pompe trashes the pump."
• Cori (III): looks like a milder Von Gierke but with normal lactate and normal uric acid, because gluconeogenesis is intact; ketosis is present and a high-protein diet helps.
• McArdle (V): exercise-induced cramps, myoglobinuria, and the second wind phenomenon. Forearm exercise shows a flat venous lactate with a normal ammonia rise — this combination is the diagnostic finding. If neither lactate nor ammonia rises, the test was submaximal (poor effort) and must be repeated; it does not exclude disease.

Best next steps

• Critical sample during hypoglycemia: glucose, lactate, ketones, free fatty acids, insulin, cortisol/GH, ammonia, and acylcarnitine profile drawn before dextrose. Ketotic hypoglycemia with hepatomegaly suggests GSD III/VI/IX, whereas GSD I shows hypoglycemia with prominent lactic acidosis and comparatively modest ketosis; hypoketotic hypoglycemia points instead to a fatty acid oxidation defect.
• Molecular genetic testing: ACMG practice guidelines for GSD I and GSD III support molecular confirmation to obviate liver biopsy and enzyme assay. Pompe disease is the exception — diagnosis rests on demonstrating deficient GAA enzyme activity (dried blood spot with a confirmatory assay), with GAA genotyping used for confirmation, CRIM status, and counseling before enzyme replacement.
• Pompe is on the federal Recommended Uniform Screening Panel, so the stem may give a positive newborn screen; confirm enzymatically, then start enzyme replacement therapy urgently (alglucosidase alfa in infantile-onset disease; avalglucosidase alfa is approved for late-onset disease), since outcome depends on treating before irreversible myocardial damage.

Distractors to avoid

• GSD Ib adds neutropenia and Crohn-like colitis; recurrent infection in a Von Gierke phenotype is Ib, not sepsis from the hepatomegaly.
• Fructose and galactose do not rescue GSD I — they enter above the block and worsen lactic acidosis; management is uncooked cornstarch and frequent feeds, not fruit juice.
• Tarui (VII) mimics McArdle but has no second wind, worsens after a high-carbohydrate meal, and shows hemolysis with reticulocytosis.